Moderna, Inc. (NASDAQ:MRNA) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 6:45 PM ET Company Participants Jamey Mock - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Jessica Fye Great. Welcome, everyone. Good afternoon. Good afternoon. My name is Jessica Fye. I'm a biotech analyst at JPMorgan, and we're continuing the 42nd Annual Healthcare Conference today with Moderna. I'm going to pass it over to the company's CFO, Jamey Mock, for a presentation and then we're ...

Pfizer Inc. (NYSE:PFE) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 6:00 PM ET Company Participants Albert Bourla - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good afternoon, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be hosting a fireside chat today with Albert Bourla, Chairman and CEO of Pfizer. So, Albert, happy New Year. Thanks for joining us. I know you want to make some quick opening remarks and th ...

Regeneron Pharmaceuticals Inc. - Key Takeaways from the 42nd Annual JPMorgan Healthcare Conference Call Company Overview - **Company**: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) - **Date**: January 8, 2024 - **Participants**: Leonard Schleifer (CEO), George Yancopoulos (CSO), Marion McCourt (EVP, Commercial) Core Industry Insights 2023 Performance Highlights - 2023 was a successful year with significant progress in both core products and pipeline development [2][5] - Key products include EYLEA and DUPIXENT, with EYLEA HD launched in August 2023 [5][7] - DUPIXENT achieved approximately $8.4 billion in sales in the first nine months of 2023, reflecting a 34% growth [8][9] EYLEA HD Launch - EYLEA HD generated $123 million in its first quarter, indicating strong market acceptance despite some prescriber hesitancy due to lack of a permanent J-code [7][8] - Approximately two-thirds of lives are covered, and a permanent J-code is expected to enhance reimbursement confidence by April 2024 [8][36] DUPIXENT Developments - DUPIXENT has been approved for five indications and is expected to launch for COPD, targeting approximately 500,000 patients in the G7 [10][20] - The product has shown a remarkable safety profile and efficacy across various allergic diseases [9][21] Pipeline and Innovation Oncology Pipeline - Regeneron is focusing on immuno-oncology, with three validated classes of immunomodulatory agents [14][15] - The company aims to be a leading oncology player by the end of the decade, with significant advancements in bispecific antibodies [10][15] - Upcoming pivotal data expected from ongoing trials, particularly in melanoma and multiple myeloma [17][57] Genetic Medicines - Regeneron is advancing genetic medicine initiatives, including CRISPR and siRNA technologies, with several programs entering clinical trials [26][27] - The collaboration with Alnylam has achieved proof-of-concept for silencing genes in the liver and brain [26] Obesity and Muscle Preservation - Regeneron is developing antibodies to improve weight loss quality by preserving muscle mass during caloric restriction [24][25] - Early data shows promising results in preclinical models, with trials expected to initiate soon [25] Future Opportunities Severe Allergies - A novel combination approach using DUPIXENT and BCMA bispecific is being explored to potentially reverse severe allergies [21][22] - Clinical trials are planned to assess the safety and efficacy of this combination [52] COPD and Other Indications - The company is preparing for the launch of DUPIXENT for eosinophilic COPD, with strong enthusiasm from pulmonologists [44][46] - Itepekimab, an IL-33 antibody, is also in development for a distinct subset of COPD patients [20] Conclusion - Regeneron is positioned for continued growth with a robust pipeline and innovative approaches across various therapeutic areas, including oncology, genetic medicine, and immunology [12][32] - The company emphasizes its commitment to scientific innovation and improving patient outcomes while maintaining a focus on corporate responsibility [32]

Biogen Inc. (NASDAQ:BIIB) J.P. Morgan 42nd Annual Healthcare Conference Summary Company Overview - **Company**: Biogen Inc. - **Industry**: Biotechnology and Pharmaceuticals - **Event**: J.P. Morgan 42nd Annual Healthcare Conference - **Date**: January 8, 2024 - **Participants**: Chris Viehbacher (CEO), Chris Schott (J.P. Morgan) Key Points Company Performance and Strategy - **2023 Reflections**: The past year was busy, with a focus on overcoming challenges from the ADUHELM controversy and declining revenues in the MS franchise. The company aimed to return to growth, which is crucial for both investors and internal motivation [4][5] - **Shift in Focus**: Biogen is transitioning from a focus on multiple sclerosis (MS) to new growth drivers, particularly LEQEMBI and Zuranolone. LEQEMBI has received full approval and is expected to address significant unmet needs in Alzheimer's treatment [5][6] - **Cost Management**: The company announced a $1 billion gross cost savings initiative, with $800 million net savings expected. This involved a complete redesign of the company to align with future success [6][7] Product Updates - **LEQEMBI**: The launch is progressing well, with a focus on establishing care pathways and addressing reimbursement issues. CMS has clarified reimbursement for LEQEMBI and related diagnostics, which is expected to facilitate patient access [12][14][15] - **Zuranolone**: Approved for postpartum depression, the product is expected to meet a significant unmet need, with a strong media presence aiding its launch [5][75] - **SKYCLARYS**: The launch is outperforming expectations, aided by active patient advocacy and a strong initial response. The company is also setting up early access programs in Europe [47][48] Research and Development - **Pipeline Focus**: The R&D pipeline has been streamlined to focus on high-value projects. Biogen is looking to expand its pipeline with assets in rare diseases and immunology, particularly through collaborations [54][55] - **Upcoming Data**: The company anticipates significant data releases in 2024, particularly regarding its ASO for tau and other ongoing studies in lupus and ALS [72][78] Market Dynamics - **Reimbursement and Diagnostics**: The introduction of blood-based diagnostics is expected to change the landscape for Alzheimer's diagnosis, potentially reducing reliance on PET scans and improving patient triage [43][44] - **Commercialization Strategy**: Biogen is focusing on establishing a strong go-to-market model in the U.S. before expanding its approach internationally. The collaboration with partners is being optimized to enhance efficiency [33][34] Financial Outlook - **2024 Expectations**: The company is shifting its revenue mix towards more product revenue, which is expected to improve gross margins. The focus will be on executing the growth strategy and managing operational expenses effectively [59][60] - **Long-term Growth**: Biogen aims to achieve a sustainable growth trajectory, with a focus on maintaining a disciplined approach to R&D investment while ensuring value creation [65][66] Conclusion - Biogen is positioned for a turnaround with a focus on innovative products and strategic cost management. The company is optimistic about its growth prospects, particularly with LEQEMBI and SKYCLARYS, while also addressing the challenges of market dynamics and operational execution [78]

Gilead Sciences, Inc. (NASDAQ:GILD) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2023 1:30 PM ET Company Participants Dan O’Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I’m Chris Schott at JPMorgan, and it’s my pleasure to be introducing Gilead today. From the Company, we’re going to have a presentation fr ...

Johnson & Johnson. (NYSE:JNJ) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 12:45 PM ET Company Participants Joaquin Duato - Chairman and CEO of J&J Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So, Joaquin, Happy New Year. Great speaking with you today. I thought it might be a good way to start the conversat ...

Company and Industry Overview * **Company**: NVIDIA Corporation (NASDAQ: NVDA) * **Industry**: Healthcare, Artificial Intelligence, Drug Discovery * **Focus**: Accelerated computing, AI, and visualization platforms for healthcare, imaging, genomics, life sciences, drug discovery, and healthcare analytics. Key Points and Arguments * **Dual Computing Transitions**: NVIDIA is driving two simultaneous computing transitions - accelerated computing and AI. These transitions are enabling generative AI and driving platform shifts in software and applications like ChatGPT. * **Digital Biology Era**: Accelerated computing and generative AI are making possible the digital biology era, including advancements in genomics, omics fields, and cell imaging. * **Drug Discovery Revolution**: Generative AI is revolutionizing drug discovery by enabling the representation of drugs, biology, and chemistry in computers. This is leading to exponential growth in the computer-aided drug discovery (CAD) industry. * **BioNeMo Platform**: NVIDIA's BioNeMo platform provides services to develop, customize, and deploy AI foundation models for drug discovery. It offers large-scale, optimized, and easy-to-use training on proprietary data and a growing collection of pretrained models. * **Amgen Collaboration**: Amgen is using NVIDIA's BioNeMo and DGX Cloud to build generative AI models and search for novel human data insights for drug discovery. * **Recursion Partnership**: Recursion is using NVIDIA's BioNeMo to offer their foundation model, Phenom-Beta, for target and hit discovery in cellular data. * **MolMIM Model**: NVIDIA's own invented foundation model, MolMIM, uses a large language model to learn chemical space and achieve state-of-the-art performance in controlled molecular generation. * **CAD Industry Growth**: The CAD industry is expected to grow significantly, driven by advancements in digital biology, generative AI, and the need for personalized medicine. Other Important Content * **NVIDIA's Healthcare Strategy**: NVIDIA is focused on building deep domain expertise, domain-specific computing platforms, and a rich ecosystem of partners to accelerate the next generation of healthcare. * **Healthcare Market Opportunity**: The healthcare market presents significant opportunities for NVIDIA, with applications in drug discovery, medical imaging, and personalized medicine. * **NVIDIA's Investment Strategy**: NVIDIA is investing in companies that use their platform, enhance it, and expand it, with a focus on data and AI-driven companies. Conclusion NVIDIA's presentation at the J.P. Morgan Healthcare Conference highlights the company's leadership in accelerated computing, AI, and drug discovery. The BioNeMo platform and partnerships with leading companies are driving innovation in the healthcare industry and positioning NVIDIA for significant growth.

Amgen Inc. (NASDAQ:AMGN) J.P. Morgan 42nd Annual Healthcare Conference 2024 January 8, 2024 ET Company Participants Robert Bradway - Chairman & CEO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about t ...

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Tim Wentworth - Chief Executive Officer Manmohan Mahajan - Interim Global Chief Financial Officer Conference Call Participants Lisa Gill - J.P. Morgan Lisa Gill Maybe it's just me. Oh, there we go. Good morning. My name is Lisa Gill, and I'm the healthcare services analyst with J.P. Morgan. It is with great pleasure this morning that I have with me Walgreens Boots Allian ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Jessica Fye - J.P. Morgan Conference Call Participants Reshma Kewalramani - Chief Executive Officer and President Jessica Fye Good morning, everyone. We're going to get started. My name is Jess Fye, I'm a Senior Biotech Analyst at J.P. Morgan, continuing the 42nd Annual Healthcare Conference this morning with Vertex. I'm joined by the Company's CEO, Reshma Kewalram ...